Physician profile
Stephanie Lance
NPI 1609315639
$5,594.44
in general payments reported to CMS, 2019-2025
19 companies · $1,256 in 2025
The $1,256 reported for 2025 was more than what 88% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $272 · 2022: $522 · 2023: $1,765 · 2024: $1,779 · 2025: $1,256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,800.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,742.26 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $882.86 | 2021-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $579.34 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Genzyme Corporation | $412.38 | 2022-2025 | |
| Qol Medical, LLC | $354.48 | 2023-2025 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $292.99 | 2024-2025 | Rezdiffra, Resmetirom |
| Celgene Corporation | $249.41 | 2022-2024 | Zeposia |
| Nestle Healthcare Nutrition INC. | $225.22 | 2021-2023 | |
| Aimmune Therapeutics, INC. | $199.07 | 2024-2025 | Zenpep |
| Phathom Pharmaceuticals, INC. | $124.43 | 2024-2025 | Voquezna |
| Janssen Biotech, INC. | $97.64 | 2024-2025 | Tremfya |
| Gilead Sciences, INC. | $84.43 | 2023-2025 | |
| Ardelyx, INC. | $77.69 | 2023-2024 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $76.99 | 2022-2025 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $65.65 | 2024-2025 | Iqirvo |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vivus LLC | $56.68 | 2025 | Qsymia |
| Intercept Pharmaceuticals, INC. | $44.46 | 2022-2023 | Ocaliva |
| Daiichi Sankyo INC. | $17.12 | 2021 | |
| Alfasigma USA, INC. | $11.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Lance listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.